CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
-
Published:2020-11-09
Issue:12
Volume:1
Page:1153-1166
-
ISSN:2662-1347
-
Container-title:Nature Cancer
-
language:en
-
Short-container-title:Nat Cancer
Author:
Solomon Isabelle, Amann Maria, Goubier Anne, Arce Vargas Frederick, Zervas Dimitrios, Qing Chen, Henry Jake Y., Ghorani EhsanORCID, Akarca Ayse U., Marafioti Teresa, Śledzińska Anna, Werner Sunderland Mariana, Franz Demane Dafne, Clancy Joanne Ruth, Georgiou Andrew, Salimu Josephine, Merchiers Pascal, Brown Mark Adrian, Flury Reto, Eckmann Jan, Murgia Claudio, Sam Johannes, Jacobsen Bjoern, Marrer-Berger Estelle, Boetsch Christophe, Belli Sara, Leibrock Lea, Benz Joerg, Koll Hans, Sutmuller Roger, Peggs Karl S., Quezada Sergio A.ORCID
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference51 articles.
1. Plitas, G. & Rudensky, A. Y. Regulatory T cells: differentiation and function. Cancer Immunol. Res. 4, 721–725 (2016). 2. Elpek, K. G., Lacelle, C., Singh, N. P., Yolcu, E. S. & Shirwan, H. CD4+ CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178, 6840–6848 (2007). 3. Golgher, D., Jones, E., Powrie, F., Elliott, T. & Gallimore, A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32, 3267–3275 (2002). 4. Jones, E. et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2, 1 (2002). 5. Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor-α) monoclonal antibody. Cancer Res. 59, 3128–3133 (1999).
Cited by
115 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|